Reuters logo
BRIEF-Nanobiotix to conduct its first clinical trial with NBTXR3 in the U.S.‍​
September 28, 2017 / 4:22 PM / 21 days ago

BRIEF-Nanobiotix to conduct its first clinical trial with NBTXR3 in the U.S.‍​

Sept 28 (Reuters) - NANOBIOTIX SA:

* PLANS TO CONDUCT ITS FIRST CLINICAL TRIAL WITH NBTXR3 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN U.S.‍​

* MEDIUM TERM OBJECTIVE IS TO TRANSFORM NON-RESPONDERS INTO CHECKPOINT INHIBITOR RESPONDERS WHILE IMPROVING PATIENT BENEFITS‍​

* TRIAL AIMS TO EVALUATE THE ABILITY OF NBTXR3 TO GENERATE AN ABSCOPAL EFFECT

* TRIAL SHOULD START WITH COMBINING NBTXR3 WITH ANY APPROVED CHECKPOINT INHIBITORS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA OR NON-SMALL CELL LUNG CANCE

* TRIAL IS AIMED AT EXPANDING THE POTENTIAL OF NBTXR3 TO RECURRENT AND METASTATIC DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below